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Abstract: Teichoic acids (TAs) are key components of the
Gram-positive bacterial cell wall that are composed of al-
ditol phosphate repeating units, decorated with alanine or
carbohydrate appendages. Because of their microhetereo-
geneity, pure well-defined TAs for biological or immuno-
logical evaluation cannot be obtained from natural sour-
ces. We present here a streamlined automated solid-phase
synthesis approach for the rapid generation of well-de-
fined glycosylated, glycerol-based TA oligomers. Building
on the use of a “universal” linker system and fluorous tag
purification strategy, a library of glycerolphosphate penta-
decamers, decorated with various carbohydrate appen-
dages, is generated. These are used to create a structurally
diverse TA-microarray, which is used to reveal, for the first
time, the binding preferences of anti-LTA (lipoteichoic
acids) antibodies at the molecular level.
Teichoic acids (TAs) are a diverse class of biopolymers com-
posed of repeating alditol phosphates and carbohydrates.
They are major constituents of the cell wall of most Gram-posi-
tive bacteria and can amount up to 70% of the dry weight of
the cell wall. Two classes of TAs exist : wall teichoic acids
(WTAs) that are covalently attached to the peptidoglycan, and
lipoteichoic acids (LTAs) that are anchored in the cell mem-
brane through a glycolipid. TAs are involved in determining
cell shape, cell division and nutrient uptake.[1] They are key vir-
ulence factors and of importance to biofilm formation and an-
tibiotic resistance.[2] TAs are targeted by the complement
system (lectin ligands)[3, 4] and are recognized by opsonophago-
cytic antibodies.[5] The most common structural TA-motif is a
polymeric glycerol phosphate backbone decorated with vari-
ous substituents, including d-alanine esters and carbohydrate
appendages. The TAs from the opportunistic pathogens Entero-
coccus faecalis, Enterococcus faecium and Staphylococcus aureus
contain a-kojibiosyl (d-glucose-(a-1,2)-glucosyl),[6] a-glucosyl[5]
or N-acetyl a-glucosamine residues,[7] respectively. Positively
charged glucosamine groups are also found in certain LTA
types.[8] Insight into how TAs interact with enzymes, receptors
and antibodies may guide new antibiotic and vaccine develop-
ments and well-defined TA fragments are indispensable tools
to fuel these studies.[9,10] Because of the microheterogeneity of
naturally sourced TAs, organic synthesis is the method of
choice to access these compounds. We, and others, have previ-
ously reported different synthetic strategies to get access to
well-defined TA structures,[11–13] and from our initial solid phase
assembly campaign, in which we generated a small set of six
TA-fragments, we identified a glycerol phosphate hexamer
bearing a single glucosyl substituent as a lead synthetic anti-
gen.[10] To be able to generate larger TA oligomers with a more
diverse substitution pattern, we here report the development
of a second generation automated solid phase approach to
generate a library of TA oligomers, featuring different carbohy-
drate appendages at various positions on the TA chain. The
method builds on the use of a “universal linker” system and
the implementation of a fluorous-tagging strategy.[14] The gen-
erated TA fragments have been used to create a TA-microarray
to characterize the binding specificity of a monoclonal anti-
body against Staphylococcus epidermidis LTA as well as serum
raised against isolated LTA from E. faecalis and serum raised
against a well-defined TA-BSA conjugate vaccine. These studies
reveal, for the first time, the recognition patterns for anti-LTA
antibodies at the molecular level, and indicate how Ab-TA
binding specificity (or lack thereof) depends on the vaccination
strategy used.
Our synthetic strategy, the targeted TA fragments and the
used building blocks are depicted in Scheme 1. We aimed at a
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library, comprising glycerol phosphates with a backbone of
15 monomers in length (Scheme 1A) and containing either an
a-glucosyl, an a-glucosaminyl or an a-N-acetyl glucosaminyl at
the C-2 of a glycerol moiety at the beginning, middle and/or
end of the pentadecamers. TA fragments with a cluster of car-
bohydrate substituents were generated as well. In all, 16 struc-
tures (1–16) were pursued as depicted in Scheme 1A. To as-
semble these TA fragments the required glycerol phosphorami-
dite building blocks 17–20 (Scheme 1B) were synthesized as
described previously.[11] In addition we synthesised the fluorous
aminospacer phosphoramidite 21[15] (See the Supporting Infor-
mation) to give all compounds with a purification handle and,
after deprotection, a ligation handle. The (commercially avail-
able) solid support used for the generation of the TA-library
bears a 3-aminopropane-1,2-diol linker that is attached to the
resin through a urea linkage (22, Scheme 1C).[16] This linker ob-
viates the need for tailor-made “pre-loaded” resins, which re-
quire the assembly of additional building blocks. The synthesis
of non-substituted glycerol phosphate 15-mer 1 commenced
with acid-mediated removal of the DMT-group in 22 followed
by 5-(benzylthio)-1-H-tetrazole (BTT)-mediated condensation of
phosphoramidite 17. Oxidation of the intermediate phosphite
to the phosphotriester and capping of the unreacted alcohols
completed the first coupling cycle. Fourteen repetitions of this
cycle delivered the resin bound pentadecamer, of which the
DMT group was removed by a final acid treatment. After instal-
lation of the fluorous linker, treatment with ammonia (2m in
methanol) released the pentadecamer from the resin. Pro-
longed treatment with aqueous ammonia then removed all re-
maining cyanoethyl groups from the phosphotriesters.
Scheme 1. A) Target TA fragments. B) Building blocks used. C) Solid phase TA synthesis. Reagents and conditions: a) 3% DCA, toluene; b) 17, 18, 19 or 20, 5-
(benzylthio)-1H-tetrazole, acetonitrile ; c) I2, pyridine, H2O, acetonitrile; d) Ac2O, N-methylimidazole, 2,6-lutidine, acetonitrile; e) NH3, MeOH; then NH4OH, H2O.
23 : 17%, 24 : 17%, 25 : 14%,26 : 7%, 27: 10%, 28 : 15%, 29 : 8%, 30 : 16%, 31: 16%, 32 : 7%, 33 : 5%, 34 6%, 35 : 5%, 36 : 6%, 37: 8%, 38 : 7%. f) H2, Pd
0, H2O.
1: 66%, 2 : 60%, 3 : 86%, 4 : 41%, 5 : 83%, 6 : 88%, 7: 36%, 8 : 51%, 9 : 79%, 10 : 39%, 11: 79%, 12 : 81%, 13 : 84%, 14 : 63%, 15 : 64%, 16 : 84%.
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Purification of the crude 15-mer was readily accomplished
using conventional reversed phase HPLC. Though we anticipat-
ed the need for a fluorous stationary phase to separate the
target compound from the deletion sequences, the C8F17-tail
proved to be lipophilic enough to provide a similar result with
a regular C18 column.
Partially protected pentadecamer 23 was obtained in 17%
overall yield, based on resin loading. The synthesis of pentade-
camer TAs 24–32, decorated with a single monosaccharide at
three different positions in the glycerol phosphate backbone
was undertaken next. After coupling glycosylated phosphora-
midites 18, 19 or 20 to the resin, fourteen benzyl-substituted
glycerol phosphate units were installed and the constructs
were capped with fluorous phosphoramidite 21. The isolated
yields for glucose decorated 24 and N-Cbz-glucosamine deco-
rated 25 (17 and 14% respectively) were in line with the yield
for undecorated oligomer 23, the N-acetyl-glucosamine deco-
rated 26 was obtained in 7% overall yield. In parallel, pentade-
camers 27–29, bearing the carbohydrate appendage at the
side of the spacer, were synthesized in yields ranging from 8
to 15%. To complete the first series of compounds, the glu-
cose- and glucosamine-decorated pentadecamers, having the
substituent in the middle of the glycerol phosphate chain (30,
31 and 32), were assembled (yields ranging from 7–16%).
Using the same protocol, fluorous and partially protected GTA-
fragments 33–38, bearing three monosaccharides, clustered or
spread over the pentadecamer backbone, were prepared. The
installation of the three carbohydrate substituted glycerol
phosphate moieties proceeded with comparable efficiency as
coupling of the non-substituted glycerol phosphates (as
judged from DMT count on the synthesizer) and the TA frag-
ments bearing three carbohydrates were isolated in 5–8%. Fi-
nally, all protecting groups (benzyl, Cbz and the fluorous Cbz)
of the obtained homogeneous, partially protected and fluorous
tagged pentadecamers 23–38 were removed by Pd-catalyzed
hydrogenolysis to provide the pure TA fragments (1–16) in 50–
90% yield.
Next, with the library of glycosylated TA-pentadecamers in
hand we generated TA-microarrays to probe the interaction
with anti-LTA antibodies.[17] Besides the TA library, generated
here, we printed several TA-fragments that were previously
synthesized. These include a series of non-substituted TA-frag-
ments of 6, 10, 14 and 20 glycerol phosphate units in length
(39–42, Figure 1A),[18] TA-hexamer 43 and kojibiosyl-TA hexa-
mer 44. We have previously shown that TA-hexamer 43 can be
used as a synthetic antigen in a TA-conjugate vaccine, which
can offer protection against E. faecalis in both active and pas-
sive immunization strategies.[10] Notably, while kojibiose has
been identified as appendage in E. faecalis TA, hexamer 44
proved to be an ineffective synthetic antigen.
In the array, we also included E. faecium WTA fragment 45
that features a di-N-acetyl galactosamine-glycerolphosphate
backbone,[19] as a negative control. All TA-fragments were
printed in varying concentrations (3, 10 and 30 mm) on epoxide
functionalized microarray glass slides.[20] With the generated
microarrays, we probed the binding of a commercially avail-
able (IBT Bioservices) mouse anti S. epidermidis monoclonal an-
tibody (used at a 1:6000 dilution), serum obtained from rabbits
Figure 1. TA-microarrays. A) Previously synthesized TA-fragments. B) Schematic representation of teichoic acid microarray set up and sera evaluation. C) Exem-
plary fluorescence readout of slides after incubation with serum. D) IgM and IgG levels in the commercially available mouse anti- S. epidermidis monoclonal
antibody (IBT Bioservices). E) IgM and IgG levels in serum obtained from rabbits immunized with LTA isolated from E. faecalis strain 12030.[22] F) IgM and IgG
levels in rabbit serum raised against a BSA-43 conjugate.[10] Data are represented at three concentrations (30 mm, 10 mm and 3 mm respectively, each spotted
in triplicate) and are normalized to the highest intensity.
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immunized with LTA isolated from E. faecalis strain 12030[21]
(used at a 1:500 dilution), and rabbit serum raised against the
previously reported BSA-TA 43 conjugate[10] (used at a 1:500 di-
lution) (Figure 1B). The fluorescence intensities (Figure 1C)
were quantified and are graphed in Figures 1D, E and F. Fig-
ure 1D depicts the interaction of the monoclonal antibodies
against S. epidermidis LTA with the immobilized TAs. It be-
comes immediately apparent that various TA stretches are rec-
ognized. There is no selective recognition for either of the car-
bohydrate appendages and it seems that the monoclonal anti-
body mainly recognizes the glycerol phosphate backbone. The
appendage of multiple carbohydrate substituents (frag-
ments 11–16) or larger carbohydrates (as in kojibiosyl TA 44)
seems to perturb binding of the antibody. The fact that unde-
corated or minimally decorated TA stretches are the main in-
teraction partners for the monoclonal antibody, accounts for
the fact that this antibody is cross reactive to various Gram-
positive bacteria, which share the glycerolphosphate backbone
as a common epitope.[5,9b] We next analyzed the serum, ob-
tained from rabbits immunized with LTA isolated from E. faeca-
lis strain 12030. Here, large differences are observed in the
binding of IgM and IgG antibodies. IgM antibodies in the
serum bound both the glycosylated and non-glycosylated TAs,
again indicating the glycerolphosphate backbone as the prime
recognition target. Surprisingly, the IgG antibodies only bound
glycosylated fragments. No binding of IgG antibodies to the
“terminally“ glycosylated fragments 2–4 and 43 was detected,
rather a preference for internally functionalized fragments (as
present in TA fragments 8–16) was observed. This lack of selec-
tive recognition of one glycosylated TA over another, can ex-
plain the cross-reactivity of serum, raised against E. faecalis
12030, with respect to other Gram-positive bacteria such as S.
aureus and E. faecium. Previously, the cross-reactivity of the
serum was attributed to recognition of the non-decorated
glycerolphosphate backbone by IgG antibodies, which clearly
is not observed for the IgG antibodies probed with these
arrays.[22] Lastly, we investigated the serum raised against a
BSA–TA 43 conjugate (Figure 1F). This microarray shows that
the serum mainly contains TA-recognizing antibodies of the
IgG-type, and only very low levels of IgM antibodies, confirm-
ing the effectiveness of the used vaccine modality. Besides
conjugate-component TA 43, also TA 2, essentially an elongat-
ed analogue of TA 43, and compounds 8 and 11, harboring the
full structure of 43 embedded in or attached to extra glycerol
phosphate residues, are recognized, showing the high specific-
ity of the serum for TA stretches with a terminal glucose ap-
pendage. The selective recognition observed with this array
highlights the power of the analytical potential of the here
presented arrays and shows, for the first time, the binding spe-
cificity of antibodies at the molecular level. In addition, they in-
dicate that it is possible to generate antibodies against a well-
defined TA epitope, that do not (or only minimally) cross react
with other (non-substituted) TA-fragments. Where it could be
expected that the glycerolphosphate backbone represents the
immunodominant epitope in LTA, it is clear that TA sequence
specific antibodies can be raised if the appropriate conjugate
is used for vaccination.
In summary, an efficient automated solid phase synthesis for
the rapid generation of a library of TA oligomers, decorated
with a diverse pattern of carbohydrate substituents, is de-
scribed. The methodology allows for the generation of long
glycerol phosphate TA stretches, with carbohydrate appendag-
es positioned at will along on the backbone. The assembled
TAs were used to generate TA-microarrays, which have been
employed to evaluate the binding preferences of monoclonal
antibodies, as well as antibodies in serum, raised against differ-
ent TA preparations. The arrays have revealed the difference in
binding selectivity (or lack thereof) of antibodies, of varying
origin. The arrays have shown that very selective antibodies
can be generated to recognize specific and well-defined TA
epitopes, with minimal binding to the common glycerol phos-
phate backbone. This in turn implies that it should be possible
to generate antibodies that selectively recognize bacterium
specific TA stretches for vaccination strategies targeting a spe-
cific Gram-positive bacterium. Clearly, the use of TAs isolated
from bacterial sources for vaccine purposes can only lead to
non-selective serum. The arrays will be valuable tools to probe
other biomolecules, such as host immune system lectins or
bacteriophage proteins, for binding and they can be used to
investigate enzymes involved in the biosynthesis and diversifi-
cation of TAs.
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